GentiBio
Margaret is the Director of Technical Development Operations at GentiBio. Margaret has worked in multiple roles across her 20+ years in the industry, including process and analytical development and GMP manufacturing and Quality Control of oligonucleotide and protein therapeutics, and more recently 6+ years of cell therapy development at Juno/Celgene/Bristol Myers-Squibb. Her work at Juno supported the Biologics License Application and approval of the Breyanzi CAR-T cell therapy product. In her most recent role at Bristol Meyers Squibb, Margaret led the Development Operations team that supported pipeline development, laboratory operations, and commercial raw material testing for CAR-T products. Margaret grew up in Boulder, CO, and obtained a BS in Chemical Engineering from the University of Colorado.
This person is not in any offices
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.